CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment

PURPOSE: Glioblastoma (GBM) patients suffer from a dismal prognosis, with standard of care therapy inevitably leading to therapy-resistant recurrent tumors. The presence of cancer stem cells (CSCs) drives the extensive heterogeneity seen in GBM, prompting the need for novel therapies specifically ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyfrid, Mathieu, Maich, William Thomas, Shaikh, Muhammad Vaseem, Tatari, Nazanin, Upreti, Deepak, Piyasena, Deween, Subapanditha, Minomi, Savage, Neil, McKenna, Dillon, Mikolajewicz, Nicholas, Han, Hong, Chokshi, Chirayu, Kuhlmann, Laura, Khoo, Amanda, Salim, Sabra Khalid, Archibong-Bassey, Blessing, Gwynne, William, Brown, Kevin, Murtaza, Nadeem, Bakhshinyan, David, Vora, Parvez, Venugopal, Chitra, Moffat, Jason, Kislinger, Thomas, Singh, Sheila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753449/
https://www.ncbi.nlm.nih.gov/pubmed/35017149
http://dx.doi.org/10.1136/jitc-2021-003289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753449/
https://www.ncbi.nlm.nih.gov/pubmed/35017149
http://dx.doi.org/10.1136/jitc-2021-003289

Ejemplares similares